Increase in β-amyloid levels in cerebrospinal fluid of children with Down syndrome

Dementia and Geriatric Cognitive Disorders

Volumn 24, Issue 5, 2007, Pages 369-374

  Englund, Hillevi ^a   Annerén, Göran ^b   Gustafsson, Jan ^c   Wester, Ulrika ^c   Wiltfang, Jens ^e   Lannfelt, Lars ^a   Blennow, Kaj ^d   Höglund, Kina ^d,f  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

Alzheimer's disease; Amyloid ; Cerebrospinal fluid; Down syndrome; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-37]; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-39]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DOWN SYNDROME; HUMAN; INFANT; MEASUREMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 35648938247     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109215     Document Type: Article

References (42)

1. Olson MI, Shaw CM: Presenile dementia and Alzheimer's disease in mongolism. Brain 1969;92:147-156.
2. Mann DM, Yates PO, Marcyniuk B: Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age-related continuum of pathological changes. Neuropathol Appl Neurobiol 1984;10:185-207.
3. Motte J, Williams RS: Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain. Acta Neuropathol (Berl) 1989;77:535-546.
4. Wisniewski KE, Dalton AJ, McLachlan C, Wen GY, Wisniewski HM: Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology 1985;35:957-961.
5. Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-185.
6. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-736.
7. Head E, Lott IT: Down syndrome and beta-amyloid deposition. Curr Opin Neurol 2004;17:95-100.
8. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC: Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 1998;43:380-383.
9. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW, Maler M, Dyrks T, Bienert M, Beyermann M, Ruther E, Kornhuber J: Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 2002;81:481-496.
10. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234.
11. Anneren G, Tuvemo T, Carlsson-Skwirut C, Lonnerholm T, Bang P, Sara VR, Gustafsson J: Growth hormone treatment in young children with Down's syndrome: effects on growth and psychomotor development. Arch Dis Child 1999;80:334-338.
12. Folin M, Baiguera S, Conconi MT, Pati T, Grandi C, Parnigotto PP, Nussdorfer GG: The impact of risk factors of Alzheimer's disease in the Down syndrome. Int J Mol Med 2003;11:267-270.
13. Cavani S, Tamaoka A, Moretti A, Marinelli L, Angelini G, Di Stefano S, Piombo G, Cazzulo V, Matsuno S, Shoji S, Furiya Y, Zaccheo D, Dagna-Bricarelli F, Tabaton M, Mori H: Plasma levels of amyloid beta 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome. Am J Med Genet 2000;95:224-228.
14. Mehta PD, Capone G, Jewell A, Freedland RL: Increased amyloid beta protein levels in children and adolescents with Down syndrome. J Neurol Sci 2007;254:22-27.
15. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K: Simultaneous measurement of beta-amyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336-345.
16. Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K: Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol 2000;43:155-160.
17. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezzini P, Bertolini S, Mann DM, Tabaton M, Gambetti P: Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 1996;2:93-95.
18. Tapiola T, Soininen H, Pirttila T: CSF tau and Abeta42 levels in patients with Down's syndrome. Neurology 2001;56:979-980.
19. Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N, Basun H, Wahlund LO, Werle E, Jauss M, Beyreuther K, Lannfelt L, Hartmann T: Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol 1999;45:504-511.
20. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R: Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.
21. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K: Cerebrospinal fluid levels of total-tau, phosphotau and a beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand 2003;179(suppl):47-51.
22. Bartha JL, Soothill PW: Plasma amyloid beta protein 1-42 levels in fetuses with Down syndrome. Early Hum Dev 2005;81:351-354.
23. Schupf N, Patel B, Silverman W, Zigman WB, Zhong N, Tycko B, Mehta PD, Mayeux R: Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 2001;301:199-203.
24. Mehta PD, Mehta SP, Fedor B, Patrick BA, Emmerling M, Dalton AJ: Plasma amyloid beta protein 1-42 levels are increased in old Down syndrome but not in young Down syndrome. Neurosci Lett 2003;342:155-158.
25. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D: APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006;38:24-26.
26. Höglund K, Syversen S, Lewczuk P, Wallin A, Wiltfang J, Blennow K: Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease. Exp Brain Res 2005;164:205-214.
27. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K: Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-379.
28. Tamaoka A, Sekijima Y, Matsuno S, Tokuda T, Shoji S, Ikeda SI: Amyloid beta protein species in cerebrospinal fluid and in brain from patients with Down's syndrome. Ann Neurol 1999;46:933.
29. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K: Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007;23:316-320.
30. Walsh DM, Selkoe DJ: Abeta oligomers - A decade of discovery. J Neurochem 2007;101:1172-1184.
31. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA: Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 2005;102:2273-2276.
32. Pitschke M, Prior R, Haupt M, Riesner D: Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 1998;4:832-834.
33. Santos AN, Torkler S, Nowak D, Schlittig C, Goerdes M, Lauber T, Trischmann L, Schaupp M, Penz M, Tiller FW, Bohm G: Detection of amyloid-beta oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer. J Alzheimers Dis 2007;11:117-125.
34. Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, Nilsson LN: Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 2005;58:147-150.
35. Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Ruther E, Kornhuber J, Wiltfang J: Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 2004;25:2912-2918.
36. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L: The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001;4:887-893.
37. Englund H, Sehlin S, Johansson A-S, Nilsson LNG, Gellerfors P, Paulie S, Lannfelt L, Ekholm Pettersson F: Sensitive ELISA detection of amyloid-β protofibrils in biological samples. J Neurochem, in press.
38. Blennow K, Hampel H: CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-613.
39. Mehta PD, Patrick BA, Dalton AJ, Aisen PS, Emmerling ME, Sersen EA, Wisniewski HM: Increased levels of tau-like protein in patients with Down syndrome. Neurosci Lett 1999;275:159-162.
40. Tapiola T, Overmyer M, Lehtovirta M, Helisalmi S, Ramberg J, Alafuzoff I, Riekkinen P Sr, Soininen H: The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 1997;8:3961-3963.
41. Van Gool SW, De Meyer G, Van de Voorde A, Vanmechelen E, Vanderstichele H: Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. Neurotoxicology 2004;25:471-480.
42. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM: Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003;24:1063-1070.